Among patients with CNS metastases at baseline , a significant improvement in overall survival ( OS ) was observed in the T-DM1 arm compared with the XL arm [ hazard ratio ( HR ) = 0.38 ; P = 0.008 ; median , 26.8 versus 12.9 months ] .